The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.

The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.

After the recent acquisition of a local OTC firm, PharmAsia News takes a closer look at Bayer’s aims of becoming the leader in the OTC sector in China.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.